First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs IVAC-M-uID (Primary) ; IVAC-W-bre1-uID (Primary)
- Indications Breast cancer
- Focus Adverse reactions; First in man
- Acronyms TNBC-MERIT
- Sponsors BioNTech
- 11 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2019.
- 11 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2019.
- 11 Oct 2016 Status changed from not yet recruiting to recruiting.